

Characterization of oligonucleotides and related impurities to support the development of drug substances

Find, relatively quantify, and confirm the structure of oligonucleotides and their impurities using the SCIEX ZenoTOF 7600 system and Molecule Profiler software

Remco van Soest, Kerstin Pohl, Yunyun Zou and Elliott Jones
SCIEX, USA

This technical note describes the identification, relative quantification and structural confirmation of oligonucleotides and related impurities. Relative quantification and full sequence coverage was achieved at levels as low as 0.3% (w/w).

Oligonucleotide therapeutics and gene therapies are rapidly gaining attention as their potency improves and delivery challenges are addressed. Modalities such as antisense oligonucleotides (ASOs) are becoming more important due to their high specificity and ability to reach formerly undruggable targets. To ensure safe drugs, methods for the identification and characterization of the full length product (FLP) and impurities are critical. High resolution mass spectrometry (HRMS) can be used for the identification of potential impurities, by comparing the measured accurate masses and isotope patterns with those calculated. However, there is a lack of powerful yet intuitive processing software, and manual interpretation is cumbersome and time consuming. Furthermore, structural confirmation leveraging MS/MS adds an additional level of complexity.

Using the Molecule Profiler software to overcome these challenges, this technical note shows the identification and relative quantification of the 5'(*n*-1), 5'(*n*-2) and 5'(*n*-3) impurities of a fully phosphorothioated FLP spiked into an FLP sample at levels between 0.1 and 10% (w/w). The software can perform relative quantification based on TOF-MS, and assign fragment ions of the potential impurities to confirm their structures, facilitating the characterization of drugs in development.

Key features of Molecule Profiler software for oligonucleotide impurity analysis

- Excellent quality and high mass accuracies for TOF-MS and TOF-MS/MS data allow for confident assignment of oligonucleotide FLP and impurities in Molecule Profiler software
- Straightforward quantification based on TOF-MS peak areas can be achieved by grouping of charge states or alternatively UV data can be leveraged for quantification
- Significant improvement of identification of low abundant impurities by boost in S/N and increased fragment assignment using the Zeno trap




Figure 1. Workflow representation for relative quantification and structural confirmation of impurities using the Molecule Profiler software. p 1

Methods

Samples and reagents: A 18-mer 2'-O-methoxyethyl phosphorothioated oligonucleotide with the same sequence as nusinersen, a drug developed for the treatment of spinal muscular atrophy, and its 5'(*n*-1), 5'(*n*-2) and 5'(*n*-3) impurities were ordered (desalted) from IDT. The ion-pairing reagents 1,1,3,3,3-hexafluoroisopropanol (HFIP, ≥ 99.8%) and diisopropylethylamine (DIEA, ≥ 99.5%), and ethylenediaminetetraacetic acid (EDTA), were purchased from Sigma Aldrich.

Sample preparation: Samples of 10 µg/mL FLP in mobile phase A containing 100 µM EDTA were spiked with the three related shortmers at 0.1, 0.3, 1, 3 and 10% (w/w relative to FLP) in order to mimic process-related impurities. The FLP was used as a control sample.

Chromatography: A Shimadzu LC-20 series HPLC system was used with water as mobile phase A and 90:10 methanol/water (v/v) as mobile phase B, both with 15 mM N,N-diisopropylethylamine and 35 mM hexafluoroisopropanol. A gradient from 20-40% B in 5 min with a 1.5 min wash step at 90% B was used at a flow rate of 0.25 mL/min. The column was a Waters ACQUITY PREMIER Oligonucleotide C18 (2.1 × 50 mm, 1.7 µm, 130 Å) at 70°C, and the injection volume was 10 µL.

Mass spectrometry: A SCIEX ZenoTOF 7600 system was used in negative polarity using an MRM^{HR} method (method details available on request). To determine the precursor masses, the data from a TOF-MS scan of the 10% spiked sample was processed using the Molecule Profiler software to extract the *m/z* values for the most abundant charge states for the FLP, the spiked-in impurities, and the desulfurization products (back-exchange of one S to O) of each of these. Collision-induced dissociation (CID) was used, and collision energies (CE) were selected that ensured the generation of fragment rich MS/MS spectra. The parameters for the final MRM^{HR} method are summarized in Table 1. The Zeno trap is located before the TOF pulser and accumulates ions during each TOF pulse, resulting in up to 90% duty cycle. Data was acquired both with Zeno trap on and off, to determine the effect of the Zeno trap functionality on MS/MS data quality.

Table 1. MS parameters.

Parameter	MS	MS/MS
Scan mode	TOF-MS	MRM ^{HR}
Polarity		negative
Gas 1		70 psi
Gas 2		70 psi
Curtain gas		30 psi
Source temperature		350°C
Ion spray voltage		-4000 V
Declustering potential		-80 V
CAD gas		7
Start mass	600 <i>m/z</i>	150 <i>m/z</i>
Stop mass	2,000 <i>m/z</i>	3,000 <i>m/z</i>
Q1 resolution	NA	Low
Accumulation time	0.1 s	0.03 s
Collision energy	-10 V	available upon request
CE spread	0 V	3 V
Zeno trap	NA	ON/OFF
ZOD threshold (CID)	NA	40,000 cps
Time bins to sum	6	12
QJet RF amplitude	190 V	190 V

Data processing: Data was processed using the SCIEX Molecule Profiler software. Considering the structure of the oligonucleotide, the number of bonds to break in the parent structure, and a comprehensive list of 83 possible standard transformations, the software identifies the different charge states of potential impurities. This assignment is based on the accurate mass match - a 20 ppm tolerance was used for the work presented in this application note - and the match between the measured and theoretical isotope patterns. Additional transformations can be added, while also custom nucleotide residues can be used by defining the 5' and 3' linkers, sugar, base and phosphate groups (Figure 2). The list of found potential impurities can be manually curated, and the different charge states of each potential impurity are grouped together for relative quantification based on the TOF-MS data.

For confirmation of the structure of each potential impurity, MS/MS spectra can be automatically annotated with *a*, *a*-B, *w*, *b*, *x*, *c*, *y* and *d* fragments (see Figure 2). Sequence coverage by consecutive fragments is automatically calculated by the software.




Figure 2. Representation of an oligonucleotide showing the different groups that can be defined for custom nucleotides. Also, the nomenclature of the MS/MS fragments used for sequence confirmation is shown in this figure, taken from the Molecule Profiler software.

Chromatography

Impurities of oligonucleotides are difficult to baseline separate from the main product with reversed phase LC while providing medium to high throughput, especially if they differ only by one or two nucleotides. Modified backbones such as phosphorothioated species are essential for improved pharmacokinetic properties and binding to the target, but complicate separation even further because they are mixtures of diastereomers, resulting in peak broadening. Figure 3 shows the separation achieved for the three spiked in impurities; only the 5'(*n*-3) showed (partial) separation from the FLP.

Relative quantification

Samples of 10 µg/mL FLP spiked with the three 5' deletion impurities at 0.1, 0.3, 1, 3 and 10% (w/w) levels were measured and analyzed using the Molecule Profiler software. Processing parameters (Figure 4) were selected to allow for the identification of the FLP and the impurities. Based on the TOF-MS data, the FLP and potential impurities are being matched to the different charge states (see *n*-3 impurity matching in Figure 5). All identified charge states can be easily grouped for an automatic calculation of the %area for the main component and each potential impurity. The %area is the sum of the TOF-MS areas of all found charge states of each identified analyte as a percentage of the total area of all analytes found. In Table 2 the %areas of the spiked-in impurities are listed for each of the spike-in levels. The purity found for the control sample is

consistent with the information from the manufacturer for products that have not been purified with HPLC.




Figure 3. XICs of one charge state for the FLP and each of the spiked-in impurities generated in Molecule Profiler software. (Partial) separation from the FLP was only achieved for the 5'(*n*-3) impurity.

A

Potential Hydrolytic Cleavages

Max. bonds to break: Min. Nucleotides: ☐ Include terminus n+1 :lud

Catabolites selected: 12

<input checked="" type="checkbox"/>	Sequence Index	Name	Neutral Formula	Neutral Mass
<input checked="" type="checkbox"/>	1-15	eC* moA* mo5meC* moT* mo...	C195H285N49O106P14S14	5890.0834
<input checked="" type="checkbox"/>	4-18	ioT* moT* moT* mo5meC* mo...	C195H283N51O107P14S14	5932.0688
<input checked="" type="checkbox"/>	1-15	eC* moA* mo5meC* moT* mo...	C195H286N49O108P15S15	5986.0269
<input checked="" type="checkbox"/>	4-18	io5meC* moT* moT* moT* mo...	C195H284N51O109P15S15	6028.0123
<input checked="" type="checkbox"/>	1-16	ieC* moA* mo5meC* moT* mo...	C208H304N51O114P15S15	6284.1433
<input checked="" type="checkbox"/>	3-18	ieC* moT* moT* moT* mo5me...	C208H301N56O113P15S15	6335.1403
<input checked="" type="checkbox"/>	1-16	ieC* moA* mo5meC* moT* mo...	C208H305N51O116P16S16	6380.0868
<input checked="" type="checkbox"/>	3-18	ioA* mo5meC* moT* moT* mo...	C208H302N56O115P16S16	6431.0838

B

m/z Tolerance

MS m/z tolerance: ppm ☐ mDa

Minimum MS peak intensity: cps

Isotope Pattern Tolerances

MS m/z tolerance: mDa

Intensity tolerance: %

Minimum Score: %

Limits

Maximum number of unexpected metabolites:

☐ Mass range window (m/z): to

Generic LC/MS Peak Finding

Perform background subtraction: ☐ Yes ☒ No

Advanced Ion Types

Use	Ion Type	Charge	Radical
<input checked="" type="checkbox"/>	[M-6H]	-6	N
<input checked="" type="checkbox"/>	[M-7H]	-7	N
<input checked="" type="checkbox"/>	[M-8H]	-8	N
<input checked="" type="checkbox"/>	[M-9H]	-9	N
<input checked="" type="checkbox"/>	[M-10H]	-10	N
<input type="checkbox"/>	[M-7H+Na]	-6	N
<input type="checkbox"/>	[M-8H+2Na]	-6	N
<input type="checkbox"/>	[M-7H+K]	-6	N
<input type="checkbox"/>	[M-8H+Na+K]	-6	N

5 adduct(s) selected Reset

Figure 4. Main settings used for the identification of potential impurities based on the TOF-MS data. A: The search space was limited to impurities with a maximum of one bond broken and a minimum length of 15 nucleotides (the FLP contained 18 residues). No internal $n-1$ or terminal $n+1$ impurities were searched for, as the main objective of this study was to demonstrate the capability of the software to find the spiked-in 5' $n-1$ to $n-3$ shortmers. B: An MS m/z tolerance of 20 ppm was used, and charge states -6 to -10 were considered.




Figure 5. Identification of potential impurity based on the TOF-MS data. A: TOF-MS showing identified charge states (yellow labeling) and suggested ID for the 5'($n-3$) at 3% spike-in level. B: Zoom-in to TOF-MS data of charge state -9 for 5'($n-3$). Blue arrow indicates the theoretical monoisotopic mass and the first seven isotopes are indicated with red arrows. An overlay of the theoretical isotopic distribution can be used for confidence in the correct assignment.

The main impurities found in the control sample were desulfurization (12.7%), and di-desulfurization (0.78%). Correlation between the spiked-in amounts, and the reported relative areas was good for the 5'($n-1$) and 5'($n-3$) impurities, with small amounts found in the control sample. For the 5'($n-2$) impurity the correlation was found to be poor. Upon further inspection of the data, this could be attributed to an overlap of the -8 charge state isotopes of the impurity with those of the -9

charge state of the drug. For relative quantification of this impurity based on MS data, a better chromatographic separation will be required. Alternatively the Analytics module in SCIEX OS software can be used to accurately quantify this impurity based on reconstruction of the TOF-MS data, or by quantification based on fragment masses using MRM^{HR} data. Note that the Molecule Profiler software also supports relative quantification based on UV data (not shown).

Table 2. Relative quantification of the spiked-in impurities. The %areas are based on the summed areas of all identified charge states of an impurity relative to the area of all identified peaks.

Spike-in (% w/w of FLP)	Spike-in (% w/w of total)	FLP (% area)	<i>n</i> -1 (%area)	<i>n</i> -2 (%area)*	<i>n</i> -3 (%area)
0	0.00	83.01	0.11	NA	0.26
0.10	0.10	82.5	0.17	0.02	0.34
0.30	0.30	80.99	0.34	0.11	0.50
1.00	0.97	81.34	0.97	0.37	1.08
3.00	2.75	75.48	2.89	1.12	2.68
10.00	7.69	63.35	8.73	6.39	8.73

* Because of an overlap of the -8 charge state isotopes of the 5'(*n*-2) impurity with the -9 charge state of the FLP (no chromatographic resolution), the charge state was excluded for relative quantification, leading to lower %area values for the 5'(*n*-2) impurity.

Correlation

The Molecule Profiler software also allows for comparing the peak areas of impurities between different samples. This feature of the software could be used to, for example, compare products that are purified using different methods, or track product quality. In Figure 6 this function of the software was used to graph the peak areas for the 5'(*n*-1) and the 5'(*n*-3) impurity for the different spike-in levels.




Figure 6. Correlation plot of area vs. %spike-in. Plots for the 5'(*n*-1) and 5'(*n*-3) impurities with good linearity are shown.

Structural confirmation

The potential impurities the software suggests are based on accurate mass and isotope pattern matching of the TOF-MS data. The location of a modification, or the actual position of all nucleotides in an impurity cannot be determined with MS only.

As the structure of an impurity can be important for its potential toxicity, confirming the correct structures is critical. The Molecule Profiler software can help in confirming the structures of each of the potential impurities by annotating the MS/MS spectra acquired for their different charge states. Allowing for *a*, *w*, *c*, *y* and *d* terminal fragments, and allowing for the loss of one base or water molecule, the Molecule Profiler software was used to annotate the different charge states and calculate the consecutive sequence coverage with an *m/z* tolerance of 10 ppm. Figure 7 shows an example of the number of consecutive residues being identified in the MS/MS data for all charge states combined for the 5'(*n*-3) impurity at the various spike-in levels. Full coverage was found for all except the lowest spike-in level (0.10%) when the Zeno trap functionality was used. Without the Zeno trap, the coverage was significantly lower, as expected. Figure 8 provides a comparison of how much more information-rich MS/MS spectra with higher S/N can be acquired using the Zeno trap versus without it.




Figure 7. Consecutive residues for different spiked-in levels of the 5'(*n*-3) impurity, with and without use of the Zeno trap. The impurity has a length of 15 nucleotides.




Figure 8. Zoom-in to the MS/MS spectrum of the 5'(*n*-3) impurity -8 charge state at the 0.3% spiked-in level. Data was acquired without using the Zeno trap (left) and with using the Zeno trap (right). Only one fragment ion was found in the MS/MS spectrum acquired without using the Zeno trap. S/N of the spectrum with Zeno trap on was approximately 10x better, showing significantly more automatically assigned fragment ions in Molecule Profiler software.

The higher quality data when using the Zeno trap therefore resulted in the software finding many more fragments. Figure 9 shows an example of identified fragment ions in the MS/MS spectra from an impurity. This information can be used to confirm the identification based on TOF-MS even further.

Fragments: 10 of 36 Proposed Formulae						
Use	Mass (m/z)	Sequence	Ion	Charge	Error (ppm)	Intensity (cps)
<input checked="" type="checkbox"/>	340.1269	moG	y1	1	1.9	190.8
<input checked="" type="checkbox"/>	379.0892	moG*moG	y2	2	-9.2	123.6
<input checked="" type="checkbox"/>	759.1913	moG*moG	y2	1	-1.9	5771.0
<input checked="" type="checkbox"/>	576.1206	moT*moG*moG	y3	2	-3.6	1462.0
<input checked="" type="checkbox"/>	1153.2532	moT*moG*moG	y3	1	0.4	67.5
<input checked="" type="checkbox"/>	514.7696	mo5meC*moT*moG*moG	y4	3	-3.4	162.2
<input checked="" type="checkbox"/>	772.6577	mo5meC*moT*moG*moG	y4	2	-3.8	241.1
<input checked="" type="checkbox"/>	654.4588	moG*mo5meC*moT*moG*moG	y5	3	-2.1	898.8
<input checked="" type="checkbox"/>	689.8710	moA*moT*moG*mo5meC*moT*moG*moG	y7	4	-7.6	197.3
<input checked="" type="checkbox"/>	790.6429	moA*moA*moT*moG*mo5meC*moT*moG*moG	y8	4	-1.6	95.8

Figure 9. Example of the annotation table in the Molecule Profiler software. The table shows the proposed fragments for a particular *m/z*, their charge states, mass accuracies and intensities. The data is from the 5'(*n*-3) impurity -8 charge state at the 3% spiked-in level, acquired using the Zeno trap. Only the *y* fragments are shown.

Conclusions

- Excellent TOF-MS data quality and mass accuracy were leveraged for the identification of FLP and spiked-in impurities down to a 0.3% level
- A fast and accurate relative quantification of oligonucleotides and their impurities based on TOF-MS or UV data can be performed in Molecule Profiler enabling fast product quality control
- The annotation of TOF-MS/MS with the most commonly found fragment ions based on a proposed structures in Molecule Profiler software greatly reduces manual workload and speeds up the correct identification of oligonucleotide-based drugs and impurities
- TOF-MS/MS data quality and fragment assignment can significantly be enhanced using the Zeno trap with the ZenoTOF 7600 system, which allows for the identification of even very low abundance impurities

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2021 DH Tech. Dev. Pte. Ltd. RUO-MKT-02-13263-A